GSK and Galapagos go separate ways on once-hyped anti-infective alliance
This article was originally published in Scrip
Executive Summary
It emerged at an R&D update provided by the Belgian biotech firm Galapagos this week that the potentially high-value anti-infectives alliance it established with GlaxoSmithKline in 2007 was dissolved last year. Galapagos took back rights to the antibacterial programmes and GSK retained those for the viral programmes in a split which Galapagos CEO Onno van de Stolpe said was prompted by Galapagos deciding that the costs of the alliance were unsustainable on its part.